Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Priorix lot-consistency and non-inferiority study versus M-M-R II in toddlers
2011-004891-12Phase 3Completed
- Sponsor
- GSK
- Start
- Oct 2012
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, Live Biotherapeutic Products → Microbiome Therapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of measles, mumps and rubella vaccine (live), M-M-R II, varicella virus vaccine live, Hepatitis A virus vaccine and Prevnar 13 in measles, mumps and rubella (2 arms), sponsored by GSK. Primary endpoints: MMR immunogenicity, Lot-to-lot consistency and 1 more. Started Oct 2012; status: completed.
02
Drugs
measles, mumps and rubella vaccine (live)M-M-R IIvaricella virus vaccine liveHepatitis A virus vaccinePrevnar 13
03
Conditions
measlesmumpsrubella
Beyond the preview
Go deeper on 2011-004891-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004891-12.